← back

 

Scientific Publications and Posters

The combined analysis of solid and liquid biopsies provides additional clinical information to improve patient care

Authors:

Ana Finzel, Helen Sadik, Gregori Ghitti, Jean-François Laes

 

Reference:

J Cancer Metastasis Treat 2018;4:21. 10.20517/2394-4722.2018.10 

 

Abstract

Aim: To investigate if the genetic information provided by sequencing of both solid and liquid biopsies can shed light on tumor heterogeneity, and to understand the clinical usefulness of adding blood profiling to standard tissue analysis in cancer care.

Methods: Data from 351 patients with stage IV solid tumors for whom molecular profiling of their solid and liquid biopsies was available were studied, with a focus on the discrepant molecular information found between tissue and blood samples.

Results: In 86% of patients, solid and liquid biopsies provided different molecular information. Discrepant gene mutations with a functional impact on the corresponding protein were studied in detail. In 97% of cases, these additional mutations provided clinical value, mainly predicting sensitivity or resistance to targeted therapies. Specifically, 42% of the mutations found only in the liquid biopsy were directly predictive of approved therapies (80% targeted therapies), while 54% were inclusion criteria for molecularly-matched trials.

Conclusion: This study suggests that the addition of blood profiling should be considered in routine clinical oncology, especially for patients with metastatic disease where integrated analysis of solid and liquid biopsies provides a more complete characterization of tumor heterogeneity and provides valuable clinical information for patient treatment.

OncoDNA's co-authors

picture of Gregori GhittiGregori Ghitti

Chief information Officer

picture of Dr. Jean-Francois LaesDr. Jean-Francois Laes

Chief Scientific Officer

picture of Dr. Ana Finzel PérezDr. Ana Finzel Pérez

Senior Medical Advisor